USPTO serial 97489090
NEOSPHERE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 21, 2025
- Examiner
- KLUWE, CHERYL D
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NEOSPHERE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leo M. Loughlin
Leo M. Loughlin ROTHWELL, FIGG, ERNST & MANBECK, PC901 New York Avenue, N.W.Suite 900 EastWASHINGTON, DC 20001Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Analysis in the field of molecular biology; Consultancy relating to pharmaceutical research and development; Consultancy in the field of pharmaceutical research; Pharmaceutical product evaluation; Biochemistry research services; Biochemical analysis; Biochemistry services in the nature of mass spectrometry based proteomics and proteomic data analysis; Biochemical research and analysis; Biological analysis; Biological research and development services; Biological research; Biological research and analysis; Biological research, clinical research and medical research; Biomedical research services; Biotechnological research relating to industry; Research relating to biotechnology; Computer programming in the medical field; Computer software programming services; Medical research laboratory services; Biological research laboratory services; Services for assessing the efficiency of pharmaceuticals being testing of pharmaceuticals; Biotechnology testing; Analysis of human serum for medical research; Analysis of human tissues for medical research; Conducting of scientific studies and research in the field of targeted protein degradation and targeted protein stabilization and related data analysis; Development of pharmaceutical drug preparations and medicines; Development and creation of computer programmes for data processing; Computer software development for others; Development of data bases; Pharmaceutical products development; computer software development; Design and development of data processing programs; Research and development of vaccines and medicines; Research relating to molecular sciences; Research on the subject of pharmaceuticals; Research and development services in the field of immunology; Research and development in the pharmaceutical and biotechnology fields; Biochemical research and development; Research and development for the pharmaceutical industry; Research and development in the field of microorganisms and cells; Clinical research in the field of targeted protein degradation and targeted protein stabilization and related data analysis; Medical and scientific research, namely, conducting clinical trials for others; Laboratory research services relating to pharmaceuticals; Medical research; Medical research in the field of oncology; Pharmaceutical drug development services; Pharmaceutical research services; Pharmaceutical research and development; Preparation of biological samples for research purposes; Preparation of biological samples for analysis in research laboratories; Preparation of biological samples for testing and analysis in research laboratories; Scientific and technological services, namely, scientific analysis in the field of targeted protein degradation and targeted protein stabilization and related data analysis; Scientific research in the field of drug discovery; Scientific research relating to biology; Scientific research and development; Scientific research for medical purposes in the area of cancerous diseases; Scientific investigations for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NEOsphere Biotechnologies GmbH
- Other trademarks owned by NEOsphere Biotechnologies GmbH
- Other trademarks owned by NEOsphere Biotechnologies GmbH
- Other trademarks in Class 042
- Similar marks named NEOSPHERE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 21, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 21, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 2, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 2, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 27, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 28, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 21, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 20, 2024 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Aug 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 16, 2024 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Aug 16, 2023 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Aug 16, 2023 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Aug 16, 2023 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 20, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 19, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 19, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 24, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 24, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 24, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 19, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 11, 2022 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Oct 11, 2022 | ALIE | ASSIGNED TO LIE | — |
| Aug 31, 2022 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jul 25, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 8, 2022 | NWAP | NEW APPLICATION ENTERED | — |